The Use of Valeriana officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5)

Journal of Supportive Oncology

Volumn 9, Issue 1, 2011, Pages 24-31

  Barton, Debra L ^{a,b,c,d,e,f,g}   Atherton, Pamela J ^a,b,c,d,e,g   Bauer, Brent A ^a,b,c,d,e,g   Moore, Dennis F ^{a,b,c,d,e,f,g}   Mattar, Bassam I ^{a,b,c,d,e,f,g}   LaVasseur, Beth I ^{a,b,c,d,e,f,g}   Rowland, Kendrith M ^{a,b,c,d,e,f,g}   Zon, Robin T ^{a,b,c,d,e,f,g}   LeLindqwister, Nguyet A ^{a,b,c,d,e,f,g}   Nagargoje, Gauri G ^{a,b,c,d,e,f,g}   Morgenthaler, Timothy I ^{a,b,c,d,e,f,g}   Sloan, Jeff A ^{a,b,c,d,e,f,g}   Loprinzi, Charles L ^{a,b,c,d,e,f,g}  

^a MAYO CLINIC ROCHESTER   (United States)

^b Metro MN CCOP   (United States)

^c Wichita Community Clinical Oncology   (United States)

^d Michigan Cancer Research Consortium   (United States)

^e Carle Cancer Center CCOP   (United States)

^f Illinois Oncology Research Association CCOP   (United States)

^g Northern Indiana Cancer Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; VALERIAN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BRIEF FATIGUE INVENTORY; CANCER FATIGUE; CANCER PATIENT; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL OUTCOMES OF SLEEP QUESTIONNAIRE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PITTSBURGH SLEEP QUALITY INDEX; PROFILE OF MOOD STATES; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SLEEP PARAMETERS; WAKEFULNESS;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYTOTHERAPY; QUESTIONNAIRES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; VALERIAN;

EID: 79955975748     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.12.008     Document Type: Article

References (60)

1. Savard J., Morin C.M. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001, 19:895-908.
2. Davidson J.R., MacLean A.W., Brundage M.D., et al. Sleep disturbance in cancer patients. Soc Sci Med 2002, 54:1309-1321.
3. Hu D.S., Silberfarb P.M. Management of sleep problems in cancer patients. Oncology (Williston Park) 1991, 5:23-27. discussion 28.
4. Fiorentino L., Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev 2006, 10:419-429.
5. Mao J.J., Armstrong K., Bowman M.A., et al. Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med 2007, 20:434-443.
6. Miller A.H., Ancoli-Israel S., Bower J.E., et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008, 26:971-982.
7. Savard J., Villa J., Ivers H., et al. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 2009, 27(31):5233-5239.
8. Oxana G., Palesh J., Roscoe K., et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010, 8(2):292-298.
9. Owen D.C., Parker K.P., McGuire D.B. Comparison of subjective sleep quality in patients with cancer and healthy subjects. Oncol Nurs Forum 1999, 26:1649-1651.
10. International Classification of Sleep Disorders. Diagnostic and Coding Manual 2005, American Academy of Sleep Medicine, American Academy of Sleep Medicine, Westchester, IL. 2nd ed.
11. Morin A.K., Jarvis C.I., Lynch A.M. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy 2007, 27:89-110.
12. Morgenthaler T., Kramer M., Alessi C., et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 2006, 29:1415-1419.
13. Roehrs T., Roth T. Sleep-wake state and memory function. Sleep 2000, 23(suppl 3):S64-S68.
14. Payne J., Piper B., Rabinowitz I., et al. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: a pilot study. Oncol Nurs Forum 2006, 33:775-783.
15. Benca R.M., Ancoli-Israel S., Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry 2004, 65(suppl 8):26-35.
16. Katz D.A., McHorney C.A. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002, 51:229-235.
17. Colten H.R., Altevogt B.M. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem 2006, Institute of Medicine (U.S.) Committee on Sleep Medicine and Research, National Academies Press, Washington DC.
18. Baker F., Denniston M., Smith T., et al. Adult cancer survivors: how are they faring?. Cancer 2005, 104:2565-2576.
19. Stiefel F.C., Kornblith A.B., Holland J.C. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer 1990, 65(4):1048-1053.
20. Ebert B., Wafford K.A., Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther 2006, 112:612-629.
21. Moller H.J. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol 1999, 19:2S-11S.
22. Barbera J., Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005, 28:301-318.
23. Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial?. J Psychiatr Pract 2006, 12:229-243.
24. Roth T., Seiden D., Sainati S., et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006, 7:312-318.
25. Holbrook A.M., Crowther R., Lotter A., et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000, 162:225-233.
26. Hall N. Taking policy action to reduce benzodiazepine use and promote self-care among seniors. J Appl Gerontol 1998, 17:318-351.
27. Johnson L.C., Chernik D.A. Sedative-hypnotics and human performance. Psychopharmacology (Berl) 1982, 76:101-113.
28. Ray W.A., Griffin M.R., Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989, 262:3303-3306.
29. Foy A., O'Connell D., Henry D., et al. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995, 50:M99-M106.
30. Gray S.L., Lai K.V., Larson E.B. Drug-induced cognition disorders in the elderly: incidence prevention and management. Drug Saf 1999, 21:101-122.
31. Tune L.E., Bylsma F.W. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr 1991, 3:397-408.
32. Houghton P.J. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999, 51:505-512.
33. Balderer G., Borbely A.A. Effect of valerian on human sleep. Psychopharmacology (Berl) 1982, 87:406-409.
34. Leathwood P.D., Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985, 51:144-148.
35. Leathwood P.D., Chauffard F., Heck E., et al. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982, 17:65-71.
36. Schulz H., Stolz C., Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 1994, 27:147-151.
37. Lindahl O., Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989, 32:1065-1066.
38. Hodgson B., Kizior R. Nursing Drug Handbook 2000, Saunders, Philadelphia.
39. Thompson C.A. USP moves forward in providing information on botanical products. Am J Health Syst Pharm 1998, 55:527-530.
40. Garges H., Varia I., Doraiswamy P., et al. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998, 280:1566-1567.
41. Budzinski J.W., Foster B.C., Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000, 7:273-282.
42. Buysse D.J., Reynolds C.F., Monk T.H., et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
43. Curran S., Andrykowsky M., Studts J. Short Form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess 1995, 7:80-83.
44. Weaver T.E., Laizner A.M., Evans L.K., et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997, 20:835-843.
45. Mendoza T.R., Wang X.S., Cleeland C.S., et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999, 85:1186-1196.
46. Lipsitz S.R., Fitzmaurice G.M., Orav E.J., et al. Performance of generalized estimating equations in practical situations. Biometrics 1994, 50:270-278.
47. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum, Hillsdale, NJ.
48. Sloan J., Symonds T., Vargas-Chanes D., et al. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inform J 2003, 37:23-31.
49. Taibi D.M., Vitiello M.V., Barsness S., et al. A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med 2009, 10:319-328.
50. Berger A., Kuhn B., Farr J., et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology 2009, 18:634-646.
51. Cankurtaran E., Ozalp E., Soygur H., et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 2008, 16:1291-1298.
52. Espie C., Fleming L., Cassidy J., et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008, 26(28):4651-4658.
53. Epstein D., Dirksen S. Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum 2007, 34(5):E51-E59.
54. Savard J., Simard S., Giguère I., et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care 2006, 4(3):219-237.
55. Savard J., Simard S., Ivers H., et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I. Sleep and psychological effects. J Clin Oncol 2005, 23(25):6083-6096.
56. Savard J., Simard S., Ivers H. Randomized study on the efficacy of cognitive behavioral therapy for insomnia secondary to breast cancer, part II. Immunologic effects. J Clin Oncol 2005, 23(25):6097-6106.
57. Sherwood P., Given B., Given C., et al. A cognitive behavioral intervention for symptom management in patients with advanced cancer. Oncol Nurs Forum 2005, 32(6):1190-1198.
58. Quesnel C., Savard J., Simard S., et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003, 71(1):189-200.
59. Davidson J., Waisberg J., Brundage M., et al. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology 2001, 10:389-397.
60. Matsuo N., Morita T. Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study. J Palliat Med 2007, 10(5):1054-1062.